Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinical‑stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications, as well as nonalcoholic fatty liver disease (NAFLD/NASH). The Company is focused on providing new treatment options for cardiom...
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinical‑stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life-threatening cardiovascular disease, focused on orphan indications, as well as nonalcoholic fatty liver disease (NAFLD/NASH). The Company is focused on providing new treatment options for cardiometabolic diseases through its complementary, convenient, cost-effective product candidate gemcabene (CI-1027 licensed from Pfizer in 2011).
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.